| St Liz Hospice, Inc 2535 W Temple Street Suite A, Los Angeles, CA, 90026 | |
| (213) 365-6499 |
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| Name | St Liz Hospice, Inc |
|---|---|
| Location | 2535 W Temple Street Suite A, Los Angeles, California |
| Hospice ID | 051744 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| Accreditation Provider | The Joint Commission (TJC) |
| SSA county code | 200 |
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| NPI Number | 1467430199 |
| Organization Name | St. Liz Hospice, Inc. |
| Address | 1910 W Sunset Blvd. Los Angeles, California, 90026 |
| Phone Number | (213)365-6499 |
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 99.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 87.8 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 100.0 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 85.2 | 93.3 |
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| Home Health Aides | 3 |
| Counselors | 2 |
| Homemakers | 1 |
| Licensed Practical or Vocational Nurses | 4 |
| Medical Social Workers | 1 |
| Physicians | 2 |
| Registered Nurses | 4 |
| Other Personnel | 1 |
| Total Employees | 18 |
|---|
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| Others | 5 |
| Total Volunteers | 5 |
|---|
News Archive
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced financial results for the first quarter of 2012.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.
The 5-mile hikes, yoga classes and communal dinners are now routines for the residents at PDX Commons Cohousing in Portland, Ore.
› Verified 4 days ago
| Kaiser Foundation Hospital Los Angeles - Hospice Location: 3699 Wishire Blvd 3rd Floor, Los Angeles, California, 90010 Phone: (213) 365-6499 |
| St Liz Hospice, Inc Location: 2535 W Temple Street Suite A, Los Angeles, California, 90026 Phone: (213) 365-6499 |
| La Hospice Location: 685 S Carondelet St 2nd Floor, Los Angeles, California, 90057 Phone: (213) 365-6499 |
| Pacific Hospice Care Corporation Location: 4520 Wilshire Boulevard Suite 101, Los Angeles, California, 90010 Phone: (213) 365-6499 |